Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer
J. Clin. Invest. Raffaele Ciampi, et al. 115:94 doi:10.1172/JCI23237 [Go to this article.]

Figure 6
Detection of V600E BRAF mutation cDNA from post-Chernobyl tumors that developed 9–12 years after exposure using LightCycler real-time PCR followed by fluorescence melting curve analysis. (A) Real-time amplification of cDNA samples. (B) Detection of point mutations by the postamplification fluorescence melting curve analysis based on a distinct melting temperature of duplexes formed between the WT probe and either WT (62.8°C) or mutant (57.0°C) sequences. The mutations in both samples are heterozygous, since both mutant and WT peaks are detectable.